AP Biosciences, Inc. (APBio) is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AP203, a bispecific antibody cancer immunotherapy targeting PD-L1 and CD137. This clearance allows APBio to proceed with Phase I human clinical trials for AP203, marking a significant milestone in the development of next-generation cancer treatments.
AP203 is a cutting-edge immunotherapy designed to simultaneously activate cytotoxic T cells while minimizing the risk of cytokine storms, an adverse immune response. By targeting PD-L1 and CD137, AP203 aims to balance treatment efficacy with reduced side effects, providing a more advanced therapeutic option for cancer patients.
The first phase of clinical trials is expected to commence shortly, with completion projected for mid-2024. The clinical trial information is available at: https://www.clinicaltrials.gov/ct2/show/NCT05473156.
AP203 will undergo the following clinical and regulatory stages:
- Phase I Clinical Trial: Expected to be completed by mid-2024, the first human trial will assess the safety, tolerability, and initial efficacy of AP203.
- Further Clinical Trials and Marketing Authorization Application: Future trials will build on Phase I data by evaluating the investigational drug’s safety and efficacy. The progress of the clinical development would further support the future marketing authorization application to healthcare authorities.
The clearance of the IND application for AP203 demonstrates APBio leadership and capability in developing innovative cancer therapies that address unmet medical needs. AP203 offers the alternative immunotherapy for cancer patients by enhancing T-cell activity and reducing adverse side effects.
The global market for anti-tumor drugs reached USD 141.3 billion in 2019, with a compound annual growth rate of 11.6%, according to a public research report by Fortune Business Insights. AP203’s development is poised to tap into this rapidly growing market, addressing critical gaps in cancer treatment through a novel therapeutic approach.
APBio is committed to advancing AP203 into the clinical trial phase. With Phase I expected to be completed by mid-2024, the company will continue to evaluate its therapeutic potential and explore future licensing opportunities.
Cautionary Statements
New drug development requires a long process, vast investments and with no guarantee of success which may pose investment risks. The investors are advised to exercise caution and conduct a thorough evaluation.
